Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Apr;84(8):1047–1051. doi: 10.1054/bjoc.2001.1729

The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer

T Saarto 1, L Vehmanen 1, I Elomaa 1, M Välimäki 2, P Mäkelä 3, C Blomqvist 4
PMCID: PMC2363866  PMID: 11308252

Abstract

In this study we report bone mineral density (BMD) changes during clodronate and antioestrogen treatment in women with breast cancer having discontinued hormone replacement therapy (HRT) at the time of operation compared to women who had not used HRT immediately before the operation. 61 postmenopausal women with operable breast cancer were treated with the adjuvant antioestrogen tamoxifen 20 mg or toremifene 60 mg daily for 3 years. All patients were randomized to clodronate (1.6 g daily orally) or control groups for 3 years. 23 patients had recently (recent users) and 38 never or not for at least 1 year before operation used HRT (non-users). BMD of lumbar spine and femoral neck were measured before antiresorptive therapy (antioestrogens and clodronate) and at 1, 2, 3 and 5 years thereafter. All patients were disease-free at the time of BMD measurements. Patients who had recently used HRT had more significant bone loss as compared to HRT non-users at 3 years in lumbar spine – 3.0% vs. + 1.2% (P< 0.001), but not in femoral neck – 0.4% vs. + 1.7% (P = 0.27). Adding 3-year clodronate treatment to antioestrogen therapy improved BMD marginally at 3 years: lumbar spine + 1.0% vs. –1.7% (P = 0.01) and femoral neck + 2.4% vs. –0.4% (P = 0.12). This was also seen at 5 years of follow-up, 2 years after termination of the antiresorptive therapy: HRT recent users vs. HRT non-users in lumbar spine –6.5% vs. +0.5% (P< 0.0001) and in femoral neck –4.8% vs. –1.5% (P = 0.38); and clodronate vs. controls in lumbar spine –1.0% vs. –3.2% (P = 0.06) and in femoral neck –0.1% vs. –5.2% (P = 0.001, respectively). The type of endocrine therapy (tamoxifen and toremifene) had no significant influence on BMD changes. We conclude from this study that postmenopausal women who have recently discontinued HRT experience more rapid bone loss than HRT non-users. Neither 3-year antioestrogen therapy alone nor antioestrogen together with clodronate could totally prevent the bone loss related to HRT withdrawal in lumbar spine, even though clodronate seemed to retard it. © 2001 Cancer Research Campaignhttp://www.bjcancer.com

Keywords: antioestrogens, bone mineral density, bisphosphonates, breast neoplasms, postmenopausal osteoporosis, toremifene

Full Text

The Full Text of this article is available as a PDF (61.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Black D. M., Cummings S. R., Karpf D. B., Cauley J. A., Thompson D. E., Nevitt M. C., Bauer D. C., Genant H. K., Haskell W. L., Marcus R. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996 Dec 7;348(9041):1535–1541. doi: 10.1016/s0140-6736(96)07088-2. [DOI] [PubMed] [Google Scholar]
  2. Christiansen C., Christensen M. S., Transbøl I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet. 1981 Feb 28;1(8218):459–461. doi: 10.1016/s0140-6736(81)91848-1. [DOI] [PubMed] [Google Scholar]
  3. Cummings S. R., Black D. M., Thompson D. E., Applegate W. B., Barrett-Connor E., Musliner T. A., Palermo L., Prineas R., Rubin S. M., Scott J. C. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998 Dec 23;280(24):2077–2082. doi: 10.1001/jama.280.24.2077. [DOI] [PubMed] [Google Scholar]
  4. Grey A. B., Stapleton J. P., Evans M. C., Tatnell M. A., Ames R. W., Reid I. R. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med. 1995 Dec;99(6):636–641. doi: 10.1016/s0002-9343(99)80251-4. [DOI] [PubMed] [Google Scholar]
  5. Harris S. T., Watts N. B., Jackson R. D., Genant H. K., Wasnich R. D., Ross P., Miller P. D., Licata A. A., Chesnut C. H., 3rd Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med. 1993 Dec;95(6):557–567. doi: 10.1016/0002-9343(93)90350-x. [DOI] [PubMed] [Google Scholar]
  6. Hosking D., Chilvers C. E., Christiansen C., Ravn P., Wasnich R., Ross P., McClung M., Balske A., Thompson D., Daley M. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med. 1998 Feb 19;338(8):485–492. doi: 10.1056/NEJM199802193380801. [DOI] [PubMed] [Google Scholar]
  7. Karpf D. B., Shapiro D. R., Seeman E., Ensrud K. E., Johnston C. C., Jr, Adami S., Harris S. T., Santora A. C., 2nd, Hirsch L. J., Oppenheimer L. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA. 1997 Apr 9;277(14):1159–1164. [PubMed] [Google Scholar]
  8. Kristensen B., Ejlertsen B., Dalgaard P., Larsen L., Holmegaard S. N., Transbøl I., Mouridsen H. T. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol. 1994 May;12(5):992–997. doi: 10.1200/JCO.1994.12.5.992. [DOI] [PubMed] [Google Scholar]
  9. Liberman U. A., Weiss S. R., Bröll J., Minne H. W., Quan H., Bell N. H., Rodriguez-Portales J., Downs R. W., Jr, Dequeker J., Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995 Nov 30;333(22):1437–1443. doi: 10.1056/NEJM199511303332201. [DOI] [PubMed] [Google Scholar]
  10. Lindsay R., Hart D. M., MacLean A., Clark A. C., Kraszewski A., Garwood J. Bone response to termination of oestrogen treatment. Lancet. 1978 Jun 24;1(8078):1325–1327. doi: 10.1016/s0140-6736(78)92402-9. [DOI] [PubMed] [Google Scholar]
  11. Love R. R., Mazess R. B., Barden H. S., Epstein S., Newcomb P. A., Jordan V. C., Carbone P. P., DeMets D. L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992 Mar 26;326(13):852–856. doi: 10.1056/NEJM199203263261302. [DOI] [PubMed] [Google Scholar]
  12. Marttunen M. B., Hietanen P., Tiitinen A., Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab. 1998 Apr;83(4):1158–1162. doi: 10.1210/jcem.83.4.4688. [DOI] [PubMed] [Google Scholar]
  13. Pouilles J. M., Tremollieres F., Ribot C. Effect of menopause on femoral and vertebral bone loss. J Bone Miner Res. 1995 Oct;10(10):1531–1536. doi: 10.1002/jbmr.5650101014. [DOI] [PubMed] [Google Scholar]
  14. Pouilles J. M., Tremollieres F., Ribot C. The effects of menopause on longitudinal bone loss from the spine. Calcif Tissue Int. 1993 May;52(5):340–343. doi: 10.1007/BF00310195. [DOI] [PubMed] [Google Scholar]
  15. Powles T. J., Hickish T., Kanis J. A., Tidy A., Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996 Jan;14(1):78–84. doi: 10.1200/JCO.1996.14.1.78. [DOI] [PubMed] [Google Scholar]
  16. Saarto T., Blomqvist C., Välimäki M., Mäkelä P., Sarna S., Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol. 1997 Apr;15(4):1341–1347. doi: 10.1200/JCO.1997.15.4.1341. [DOI] [PubMed] [Google Scholar]
  17. Saarto T., Blomqvist C., Välimäki M., Mäkelä P., Sarna S., Elomaa I. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer. 1997;75(4):602–605. doi: 10.1038/bjc.1997.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Storm T., Thamsborg G., Steiniche T., Genant H. K., Sørensen O. H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990 May 3;322(18):1265–1271. doi: 10.1056/NEJM199005033221803. [DOI] [PubMed] [Google Scholar]
  19. Valavaara R., Pyrhönen S., Heikkinen M., Rissanen P., Blanco G., Thölix E., Nordman E., Taskinen P., Holsti L., Hajba A. Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study. Eur J Cancer Clin Oncol. 1988 Apr;24(4):785–790. doi: 10.1016/0277-5379(88)90316-1. [DOI] [PubMed] [Google Scholar]
  20. Ward R. L., Morgan G., Dalley D., Kelly P. J. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner. 1993 Aug;22(2):87–94. doi: 10.1016/s0169-6009(08)80220-6. [DOI] [PubMed] [Google Scholar]
  21. Watts N. B., Harris S. T., Genant H. K., Wasnich R. D., Miller P. D., Jackson R. D., Licata A. A., Ross P., Woodson G. C., 3rd, Yanover M. J. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990 Jul 12;323(2):73–79. doi: 10.1056/NEJM199007123230201. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES